- Home
- AACG vs LSTA Comparison
AACG vs LSTA Comparison
Compare AACG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- LSTA
- Stock Information
- Founded
- AACG 1999
- LSTA 1980
- Country
- AACG China
- LSTA United States
- Employees
- AACG N/A
- LSTA N/A
- Industry
- AACG Other Consumer Services
- LSTA Misc Health and Biotechnology Services
- Sector
- AACG Real Estate
- LSTA Health Care
- Exchange
- AACG Nasdaq
- LSTA Nasdaq
- Market Cap
- AACG 27.0M
- LSTA 31.2M
- IPO Year
- AACG N/A
- LSTA N/A
- Fundamental
- Price
- AACG $0.94
- LSTA $2.55
- Analyst Decision
- AACG
- LSTA Strong Buy
- Analyst Count
- AACG 0
- LSTA 1
- Target Price
- AACG N/A
- LSTA $15.00
- AVG Volume (30 Days)
- AACG 21.3K
- LSTA 24.3K
- Earning Date
- AACG 03-25-2025
- LSTA 02-27-2025
- Dividend Yield
- AACG N/A
- LSTA N/A
- EPS Growth
- AACG N/A
- LSTA N/A
- EPS
- AACG N/A
- LSTA N/A
- Revenue
- AACG $35,747,843.00
- LSTA N/A
- Revenue This Year
- AACG N/A
- LSTA N/A
- Revenue Next Year
- AACG N/A
- LSTA N/A
- P/E Ratio
- AACG N/A
- LSTA N/A
- Revenue Growth
- AACG 15.80
- LSTA N/A
- 52 Week Low
- AACG $0.50
- LSTA $2.19
- 52 Week High
- AACG $1.65
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- AACG 58.94
- LSTA 42.39
- Support Level
- AACG $0.86
- LSTA $2.41
- Resistance Level
- AACG $0.93
- LSTA $2.66
- Average True Range (ATR)
- AACG 0.05
- LSTA 0.19
- MACD
- AACG 0.01
- LSTA 0.01
- Stochastic Oscillator
- AACG 65.38
- LSTA 42.06
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.